Showing 6141-6150 of 7756 results for "".
- FDA Nod for Stelara in Pediatric Psoriatic Arthritishttps://practicaldermatology.com/news/fda-nod-for-stelara-in-pediatric-psoriatic-arthritis/2461284/The FDA approved Stelara (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). Stelara is a fully human monoclonal antibody that selectively inhibits both interleukin (IL)-12 and IL-23, two cytokines thought to
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhib
- Incyte's Opzelura Adds Vitiligo Indicationhttps://practicaldermatology.com/news/incytes-opzelura-adds-vitiligo-indication/2461274/Opzelura™ (ruxolitinib) cream 1.5% from Incyte is now approved for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is the first and only FDA-approved treatment for repigmentation in patients with vitiligo and the only topica
- Dermaliq Forms New Scientific and Medical Advisory Boardhttps://practicaldermatology.com/news/dermaliq-forms-new-scientific-and-medical-advisory-board/2461270/Dermaliq Therapeutics, Inc. has formed a Scientific and Medical Advisory Board. New members include Gordon Dow, Xavier Yon, Michael Kuligowski, MD, PhD, and R. Todd Plott, MD. The Advisory Board is composed of key clinical investigators and industry veterans in the field who suppor
- Novan's Berdazimer Gel Performs Well in Phase 3 for Molluscum: Studyhttps://practicaldermatology.com/news/novans-berdazimer-gel-performs-well-in-phase-3-for-molluscum-study/2461269/Berdazimer gel, 10.3% from Novan, Inc., significantly out-performed placebo for the treatment of molluscum, according to results of the B-SIMPLE 4 pivotal Phase 3 clinical study published in JAMA Dermatology</
- Health Canada Clears Cutera’s AviClearhttps://practicaldermatology.com/news/health-canada-clears-cuteras-aviclear/2461268/Health Canada has cleared Cutera, Inc.’s AviClear for the treatment of mild, moderate, and severe acne. This Health Canada announcement comes on the heels of the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, in March 2022. In addition
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- New from BTL: Meet The EMSCULPT NEO Edge Applicator for the Lateral Abdomenhttps://practicaldermatology.com/news/new-from-btl-meet-the-emsculpt-neo-edge-applicator-for-the-lateral-abdomen/2461265/BTL is launching the new Edge Applicators to treat the entire lateral abdomen. Shipping will begin in S
- Systemic Inhibition of S100A9 May Reduce Severity of PsO, PsAhttps://practicaldermatology.com/news/systemic-inhibition-of-s100a9-may-reduce-severity-of-pso-psa/2461262/The severity of psoriasis and psoriatic arthritis can be reduced by inhibiting S100A9 systemically throughout the whole body rather than locally on the skin, according to a new study. By way of background, S100A9 activation in skin and immune cells has been identified as a risk factor f
- Vitamin D During Pregnancy May Cut Eczema Risk in Babieshttps://practicaldermatology.com/news/vitamin-d-during-pregnancy-may-cut-eczema-risk-in-babies/2461256/Taking Vitamin D supplements during pregnancy could substantially reduce the chances of babies developing atopic eczema, according to a new study by University of Southampton researchers. The research, published in the